Synthetic lethality between HER2 and transaldolase in intrinsically resistant HER2-positive breast cancers - Wikidata - awgldk - TriplyDB

Synthetic lethality between HER2 and transaldolase in intrinsically resistant HER2-positive breast cancers

Synthetic lethality between HER2 and transaldolase in intrinsically resistant HER2-positive breast cancers

http://www.wikidata.org/entity/Q57464691

about

Synthetic lethality between HER2 and transaldolase in intrinsically resistant HER2-positive breast cancers

http://www.wikidata.org/entity/Q57464691

description

article publié dans Nature Communications

@fr

im Oktober 2018 veröffentlichter wissenschaftlicher Artikel

@de

scientific article published in Nature Communications

@en

wetenschappelijk artikel

@nl

наукова стаття, опублікована в жовтні 2018

@uk

name

Synthetic lethality between HE ...... t HER2-positive breast cancers

@en

Synthetic lethality between HE ...... t HER2-positive breast cancers

@nl

type

label

Synthetic lethality between HE ...... t HER2-positive breast cancers

@en

Synthetic lethality between HE ...... t HER2-positive breast cancers

@nl

prefLabel

Synthetic lethality between HE ...... t HER2-positive breast cancers

@en

Synthetic lethality between HE ...... t HER2-positive breast cancers

@nl

P1433

Q57464691-5A06881B-1C8E-4ED2-A86A-54ABE517F429

P1476

Q57464691-7968998E-AE78-42A4-A03D-664DA810D731

P2093

Q57464691-09739005-333A-48AA-99FF-41BF860FE6D6

Q57464691-1C9BFF1F-8A11-4E30-81F8-8FAD0406542B

Q57464691-38EB375D-9E0C-42FD-9F15-38BF08B6156C

Q57464691-5F0C47A7-EDCD-4CCC-A88E-39F9C9E6D7E2

Q57464691-610C998C-F2C5-4781-A7AB-15DCF0BFACF2

Q57464691-6BFFC4BD-57F8-4D4F-9E2E-001938EC635A

Q57464691-925E97A6-5AE7-4199-A458-2EB48BDDE114

Q57464691-9838D58B-6284-488D-9CEF-9F893C5BBDD0

Q57464691-A9C502A2-7254-4699-93FC-F4C2E9D833E9

Q57464691-AEE576A5-8127-4B81-8D1F-520FFA278F18

P2860

Q57464691-0242DE8F-81FD-4F09-9405-1D0A284505B3

Q57464691-10338186-AB97-4C89-AA8A-B132941D2B6D

Q57464691-153F5DB0-44D4-4193-BDC3-4F12844715B0

Q57464691-177AC639-6701-476F-8093-E9E4CE0748E6

Q57464691-17AF5592-C397-4A21-8244-8BB7C0DD12D6

Q57464691-220D7567-B47B-41CA-A771-1F7FEF916E9C

Q57464691-2A94B7EC-1439-4F12-9666-A82BFC8BE6F7

Q57464691-2D02C1A6-C829-4F2E-8FC0-F58F23167217

Q57464691-3B9566BF-071B-4ACE-9687-84125F76804F

Q57464691-429CED29-894C-429F-B09E-FDB195FB311C

P2888

Q57464691-48909FBD-0C1C-4DC7-B6FA-839DD35AFCD7

P304

Q57464691-A80AE184-A01A-4E0D-BB54-84C47652040C

P31

Q57464691-630BC190-FF19-4306-9837-BBD20D5BCC9A

P356

Q57464691-83A2F946-47E8-407C-926E-B8DCE9105DD2

P407

Q57464691-A9B7289D-79D1-47DF-AFBF-FBB7D8A11878

P433

Q57464691-06A6BA06-D24D-4154-ADF9-4526E0607682

P478

Q57464691-BA0F0FBF-F9A5-465C-AB80-C88443B3A31D

P577

Q57464691-32C2E5FA-320F-4D6F-8382-1590B70525D6

P6179

Q57464691-257424FF-29FE-4AA0-9475-9A1B4046FE0E

P698

Q57464691-D44636B4-D7A7-452B-9305-ACEEF905AC11

P921

Q57464691-0A3DB363-3408-4197-8344-5F83732BC3DB

P932

Q57464691-CF64D12A-2AC5-49F9-A219-BB0234D5BC4F

P356

S41467-018-06651-X

P1433

Nature Communications

P1476

Synthetic lethality between HE ...... t HER2-positive breast cancers

@en

P2093

Chang Gong

http://www.w3.org/2001/XMLSchema#string

De Huang

http://www.w3.org/2001/XMLSchema#string

Er-Wei Song

http://www.w3.org/2001/XMLSchema#string

Gehao Liang

http://www.w3.org/2001/XMLSchema#string

Handan Xiang

http://www.w3.org/2001/XMLSchema#string

Junying Chen

http://www.w3.org/2001/XMLSchema#string

Kevin H Lin

http://www.w3.org/2001/XMLSchema#string

Kris C Wood

http://www.w3.org/2001/XMLSchema#string

Lifeng Yuan

http://www.w3.org/2001/XMLSchema#string

Peter B Alexander

http://www.w3.org/2001/XMLSchema#string

P2860

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

Lapatinib plus capecitabine for HER2-positive advanced breast cancer.

A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer.

PTEN, PIK3CA, p-AKT, and p-p70S6K status: association with trastuzumab response and survival in patients with HER2-positive metastatic breast cancer.

Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer.

Trastuzumab emtansine for HER2-positive advanced breast cancer.

Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer

Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene

Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial

TBX3 and its isoform TBX3+2a are functionally distinctive in inhibition of senescence and are overexpressed in a subset of breast cancer cell lines

P2888

s41467-018-06651-x

P304

4274

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/S41467-018-06651-X

http://www.w3.org/2001/XMLSchema#string

P407

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

9

http://www.w3.org/2001/XMLSchema#string

P577

2018-10-15T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1107514468

http://www.w3.org/2001/XMLSchema#string

P698

30323337

http://www.w3.org/2001/XMLSchema#string

P921

general chemistry

P932

6189078

http://www.w3.org/2001/XMLSchema#string